Last reviewed · How we verify
Benzathine penicillin G
Benzathine penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking.
Benzathine penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking. Used for Streptococcal pharyngitis and tonsillitis, Acute rheumatic fever prophylaxis, Secondary prophylaxis of rheumatic heart disease.
At a glance
| Generic name | Benzathine penicillin G |
|---|---|
| Sponsor | International Maternal Pediatric Adolescent AIDS Clinical Trials Group |
| Drug class | Beta-lactam antibiotic |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
As a beta-lactam antibiotic, benzathine penicillin G irreversibly inhibits transpeptidase enzymes responsible for cross-linking peptidoglycan strands in the bacterial cell wall. This disruption of cell wall integrity leads to bacterial cell lysis and death. The benzathine salt formulation provides sustained release, allowing for long-acting intramuscular dosing.
Approved indications
- Streptococcal pharyngitis and tonsillitis
- Acute rheumatic fever prophylaxis
- Secondary prophylaxis of rheumatic heart disease
- Early syphilis
- Congenital syphilis
Common side effects
- Allergic reaction (rash, urticaria)
- Anaphylaxis
- Injection site pain or swelling
- Diarrhea
- Nausea
Key clinical trials
- Spotting Syphilis: A Dual Point-of-Care Syphilis Screening Initiative in a Low-Resource Healthcare Setting (NA)
- Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy
- APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) (PHASE2)
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics (PHASE4)
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: